The global digital biomarkers market is projected to be worth over USD 22 billion by 2030::::

Roots Analysis has done a detailed study on “Digital Solutions for Biomarkers Market, 2021-2030 covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 270+ page report, which features 135+ figures and 140+ tables, please visit https://www.rootsanalysis.com/reports/digital-biomarkers-market.html
Key Market Insights 
Presently, over 30 players are engaged in the development of digital solutions for different types of biomarkers; these solutions can be analyzed in silico, for a variety of diseases / clinical conditions
The pipeline features a variety of digital solutions, which are being evaluated across different stages of development, designed to identify and analyze a diverse set of biomarkers, for use across a range of indications
In order to maintain a competitive edge, companies engaged in the development of digital solutions for biomarkers are presently focusing on the integration of advanced features into their respective product offerings
In the short to mid-term, considering their applicability across more than 35 target indications, more solutions for physiological / vocal biomarkers are likely to be developed for patient diagnosis / monitoring
Case Study: The gradual shift towards incorporation of digital health tools to overcome physical confines of clinical environment is evident from ~40 global events that have recently been organized for digital biomarkers
Foreseeing a lucrative future, several public and private investors have made investments worth around USD 1 billion, across over 110 publicly reported funding instances
The growing interest of stakeholders is also evident from the rise in partnership activity within this domain; in fact, the maximum number of collaborations related to digital solutions for biomarkers were inked in 2020
In order to tap into the lucrative opportunity associated with these modern solutions, several big pharma players have also undertaken diverse initiatives in this field, ranging from product development to strategic investments
The market for digital solutions for biomarkers is expected to witness growth at an annualized rate of about 32%, from 2021-2030, with revenues from product sales coming in via both B2B and B2C channels
The projected future opportunity for companies engaged in this field is expected to be well distributed across different therapeutic areas, purposes of solutions, and key geographical regions
For more information, please visit https://www.rootsanalysis.com/reports/digital-biomarkers-market.html
Table of Contents
1.         PREFACE                     
1.1.       Scope of the Report
1.2.       Research Methodology
1.3.       Chapter Outlines
 
2.         EXECUTIVE SUMMARY
 
3.         INTRODUCTION
3.1        Chapter Overview
3.2.       Digitization in the Healthcare Sector
3.3.       Next-Generation Healthcare Solutions
Chapter Overview
3.2.       Overview of Digital Biomarkers
3.2.1     Classification of Digital Biomarkers                   
3.2.2     Key Advantages and Limitations
3.3.       Digital Biomarker-related Product Development and Commercialization Path
3.3.1.    Product Discovery and Development
3.3.2.    Validation and Regulatory Submissions
3.3.3.    Distribution and Marketing
3.4.       Prevalent Trends Related to Digital Biomarkers
3.4.1.    Emerging Focus Areas
3.4.2.    Key Historical Trends
3.4.3.    Geographical Activity
 
4.         MARKET LANDSCAPE
4.1.       Chapter Overview
4.2.       Digital Solutions for Biomarkers: Overall Market Landscape
4.2.1.    Analysis by Current Status
4.2.2.    Analysis by Content of Solution
4.2.3.    Analysis by Purpose of Solution
4.2.4.    Analysis by Type of Biomarker
4.2.5.    Analysis by Target Indication(s)
4.2.6.    Analysis by Therapeutic Area
4.2.7.    Analysis by Target Population
4.2.8.    Analysis by Prescription Requirement
4.3.       Digital Solutions for Biomarkers: Developer Landscape
4.3.1.    Analysis by Year of Establishment
4.3.2.    Analysis by Company Size
4.3.3.    Analysis by Type of Business Model Used
4.3.4     Analysis by Location of Headquarters
4.4.       Leading Developers: Analysis by Number of Digital Solutions for Biomarker
4.5.       Digital Solutions for Biomarkers: Information on Additional Players
 
5.         KEY INSIGHTS
5.1.       Chapter Overview
5.2.       4D Bubble Analysis: Analysis by Portfolio Strength, Type of Biomarker and Company Size
5.3.       Grid Representation: Analysis by Current Status, Content of Solution and Therapeutic Area
5.4.       Treemap Representation: Analysis by Therapeutic Area and Company Size
5.5.       World Map Representation: Analysis by Location of Headquarters
5.6.       Current and Future Market Landscape Trends Analysis
 
6.         COMPANY PROFILES
6.1.       Chapter Overview
6.2.       Acculi Labs
6.2.1     Company Overview
6.2.2.    Product Portfolio
6.2.3.    Recent Developments and Future Outlook
6.3.       Canary Health Technologies
6.3.1.    Company Overview
6.3.2.    Product Portfolio
6.3.3.    Recent Developments and Future Outlook
6.4.       Empatica
6.4.1.    Company Overview
6.4.2.    Product Portfolio
6.4.3.    Recent Developments and Future Outlook
6.5        IXICO
6.5.1.    Company Overview
6.5.2.    Product Portfolio
6.5.3.    Recent Developments and Future Outlook         
6.6.       Kinsa
6.6.1.    Company Overview
6.6.2.    Product Portfolio
6.6.3.    Recent Developments and Future Outlook
6.7.       Progentec Diagnostics
6.7.1.    Company Overview
6.7.2.    Product Portfolio
6.7.3.    Recent Developments and Future Outlook         
6.8.       Vocalis Health
6.8.1.    Company Overview
6.8.2.    Product Portfolio
6.8.3     Recent Developments and Future Outlook
7.         PRODUCT COMPETITIVENESS ANALYSIS
7.1.       Chapter Overview
7.2.       Key Parameters and Methodology
7.3.       Product Competitiveness Analysis
7.3.1.    Product Competitiveness Analysis: Idiosyncratic Biomarkers
7.3.2.    Product Competitiveness Analysis: Physiological Biomarkers
7.3.3.    Product Competitiveness Analysis: Vocal Biomarkers
7.3.4.    Product Competitiveness Analysis: Other Biomarkers
8.         GLOBAL EVENTS ANALYSIS
8.1.       Chapter Overview
8.2.       Scope and Methodology
8.3.       Global Events Related to Digital Biomarkers
8.3.1.    Analysis by Year of Occurrence
8.3.2.    Analysis by Event Platform
8.3.3.    Analysis by Geography
8.3.4.    Analysis by Type of Event
8.3.5.    Evolutionary Trend in Key Agenda / Event Agenda
8.3.6.    Most Active Event Organizers
8.3.7.    Most Active Players in Terms of Event Participation
8.3.8.    Analysis by Seniority Level of Participants
9.         FUNDING AND INVESTMENT ANALYSIS
9.1.       Chapter Overview
9.2.       Types of Funding
9.3.       Digital Solutions for Biomarkers: Funding and Investment Analysis
9.3.1.    Analysis by Number of Funding Instances
9.3.2.    Analysis by Amount Invested
9.3.3.    Analysis by Type of Funding
9.3.4.    Analysis by Type of Biomarker
9.3.5.    Analysis by Therapeutic Area
9.3.6.    Analysis by Geography
9.3.7.    Most Active Players: Analysis by Number of Instances
9.3.8.    Most Active Players: Analysis by Amount Invested
9.3.9.    Most Active Investors: Analysis by Number of Instances
                       
9.4        Concluding Remarks
 
10.        PARTNERSHIPS AND COLLABORATIONS 
10.1.     Chapter Overview
10.2.     Partnership Models
10.3.     Digital Solutions for Biomarkers: Recent Partnerships and Collaborations
10.3.1.  Analysis by Year of Partnership
10.3.2.  Analysis by Type of Partnership
10.3.2.1 Analysis by Type of Partnership and Year of Partnership
10.3.2.2 Analysis by Type of Partnership and Company Size
10.3.3.  Analysis by Type of Partner
10.3.3.1. Analysis by Type of Partner and Year of Partnership
10.3.3.2. Analysis by Type of Partner and Type of Partnership
10.3.3.3. Analysis by Type of Partner and Company Size
10.3.4.  Analysis by Type of Biomarker
10.3.4.1. Analysis by Type of Biomarker and Year of Partnership
10.3.4.2. Analysis by Type of Biomarker and Type of Partnership
10.3.5.  Analysis by Therapeutic Area
10.3.5.1. Analysis by Therapeutic Area and Year of Partnership
10.3.5.2. Analysis by Therapeutic Area and Type of Partner
10.3.6.  Most Active Players: Analysis by Number of Partnerships
10.3.7.  Regional Analysis
10.3.8.  Intercontinental and Intracontinental Agreements
 
11.        BIG PHARMA INITIATIVES
11.1.     Chapter Overview
11.2.     Scope and Methodology
11.3.     Digital Biomarker-related Initiatives of Big Pharma Players
11.3.1.  Clinical Research Activity
11.3.2.  Partnership Activity
11.3.3.  Funding and Investments
11.3.4.  Participation in Global Events
11.3.5.  Research Publications
11.4.     Benchmark Analysis of Big Pharmaceutical Players
11.4.1.  Spider Web Analysis: Company A
11.4.2.  Spider Web Analysis: Company B
11.4.3.  Spider Web Analysis: Company C
11.4.4.  Spider Web Analysis: Company D
11.4.5.  Spider Web Analysis: Company E
11.4.6.  Spider Web Analysis: Company F
11.4.8.  Spider Web Analysis: Company G
11.4.8.  Spider Web Analysis: Company H
11.4.9.  Spider Web Analysis: Company I
11.4.10. Spider Web Analysis: Company J
11.4.11. Spider Web Analysis: Company K
11.4.12. Spider Web Analysis: Company L
11.4.13. Spider Web Analysis: Company M
 
12.        MARKET FORECAST
12.1.     Chapter Overview
12.2.     Forecast Methodology and Key Assumptions
12.3.     Digital Solutions for Biomarkers Market, 2021-2030
12.4.     Digital Solutions for Biomarkers Market: Distribution by Content of Solution
12.4.1. Digital Solutions for Biomarkers Market for Standalone Software Applications, 2021-2030
12.4.2. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + AI Support), 2021-2030
12.4.3. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + Device), 2021-2030
12.4.4. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + AI Support + Device), 2021-2030
12.4.5. Digital Solutions for Biomarkers Market for Other Content of Solutions, 2021-2030
12.5.     Digital Solutions for Biomarkers Market: Distribution by Purpose of Solution
12.5.1. Digital Solutions for Biomarkers Market for Diagnosis, 2021-2030
12.5.2. Digital Solutions for Biomarkers Market for Early Screening, 2021-2030
12.5.3. Digital Solutions for Biomarkers Market for Monitoring, 2021-2030
12.5.4. Digital Solutions for Biomarkers Market for Predictive Insights, 2021-2030
12.6.     Digital Solutions for Biomarkers Market: Distribution by Type of Biomarker
12.6.1. Digital Solutions for Cognitive Biomarkers Market, 2021-2030
12.6.2. Digital Solutions for Idiosyncratic Biomarkers Market, 2021-2030
12.6.3. Digital Solutions for Physiological Biomarkers Market, 2021-2030
12.6.4. Digital Solutions for Vocal Biomarkers Market, 2021-2030
12.6.5. Digital Solutions for Other Biomarkers Market, 2021-2030
12.7.     Digital Solutions for Biomarkers Market: Distribution by Therapeutic Area
12.7.1. Digital Solutions for Biomarkers Market for Autoimmune Disorders, 2021-2030
12.7.2. Digital Solutions for Biomarkers Market for Cardiovascular Disorders, 2021-2030
12.7.3. Digital Solutions for Biomarkers Market for Infectious Disorders, 2021-2030
12.7.4. Digital Solutions for Biomarkers Market for Mental Health Problems, 2021-2030
12.7.5. Digital Solutions for Biomarkers Market for Neurological Disorders, 2021-2030
12.7.6. Digital Solutions for Biomarkers Market for Respiratory Disorders, 2021-2030
12.7.7. Digital Solutions for Biomarkers Market for Substance Use Disorders, 2021-2030
12.7.8. Digital Solutions for Biomarkers Market for Other Disorders, 2021-2030
12.8.     Digital Solutions for Biomarkers Market: Distribution by Business Model
12.8.1. Digital Solutions for Biomarkers Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2021-2030
12.8.2. Digital Solutions for Biomarkers Market for B2C Model (Patients and Caregivers), 2021-2030
12.9.     Digital Solutions for Biomarkers Market: Distribution by Key Geographical Regions
12.9.1. Digital Solutions for Biomarkers Market in North America, 2021-2030
12.9.2.  Digital Solutions for Biomarkers Market in Europe, 2021-2030
12.9.3. Digital Solutions for Biomarkers Market in Asia-Pacific, 2021-2030
12.9.4. Digital Solutions for Biomarkers Market in Middle East and North Africa (MENA), 2021-2030
12.9.5. Digital Solutions for Biomarkers Market in Rest of the World, 2021-2030
12.10.   Concluding Remarks
 
13.        IMPACT OF COVID-19 PANDEMIC ON DIGITAL SOLUTIONS FOR                  BIOMARKERS MARKET
13.1.     Chapter Overview
13.2.     Impact of COVID-19 Pandemic on Digital Solutions for Biomarkers Market
13.2.1.  Impact on Future Market Opportunity for Digital Solutions for Biomarkers 
13.3.     Current Opinions and Key Initiatives of Key Players
13.4.     Recuperative Strategies for Developer Businesses
13.4.1.  Strategies for Implementation in the Short / Mid Term
13.4.2.  Strategies for Implementation in the Long Term
 
14.        CONCLUSION
14.1.     Chapter Overview
14.2.     Key Takeaways
 
15.        EXECUTIVE INSIGHTS
15.1.     Chapter Overview
15.2.     Tilak Healthcare
15.2.1.  Company Snapshot
15.2.2.  Interview Transcript: Edouard Gasser, Co-Founder and Chief Executive Officer
15.3.     Vocalis Health
15.3.1.  Company Snapshot
15.3.2.  Interview Transcript: Michael Seggev, Chief Commercial Officer
 
16.        APPENDIX I: TABULATED DATA
 
17.        APPENDIX II: LIST OF COMPANIES AND ORGANIZATION
 
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com



You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
1448 Posts

Made with by Mamby